Trial Profile
A retrospective study of Omalizumab in severe chronic spontaneous urticaria in real clinical practice
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 May 2018
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Urticaria
- Focus Therapeutic Use
- 09 May 2018 New trial record